JPMorgan Starts Eli Lilly (LLY) at Overweight, Added to Analyst Focus List

JPMorgan analyst Chris Schott initiates coverage on Eli Lilly (NYSE: LLY) with a Overweight rating and a price target of $140.00.

• Schoot puts a Overweight recommendation on the equity following a period of Not Rated.
• Adds the name to the Analyst Focus List.
• Says premium valuation is warranted given the company above peer top and bottom-line growth.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $123.50 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform